Introduction
============

As the survival times of non-small cell lung cancer (NSCLC) patients have been significantly prolonged in recent years, leptomeningeal metastasis (LM) has exhibited a tendency for increasing in these patients ([@b1-ol-0-0-4783]--[@b3-ol-0-0-4783]). The median survival time of NSCLC patients with LM is ≤2 months if the patients do not receive any treatment ([@b1-ol-0-0-4783],[@b4-ol-0-0-4783]).

For the treatment of LM in NSCLC patients, numerous different interventions and regimens \[such as radiotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs), systemic chemotherapy, intrathecal chemotherapy (ITC)\] have been attempted. Although each intervention has been reported to be effective, no intervention has been confirmed to be the most effective ([@b5-ol-0-0-4783]--[@b14-ol-0-0-4783]). In fact, the most effective intervention has not been established for LM from many other types of tumor ([@b15-ol-0-0-4783]--[@b18-ol-0-0-4783]). This is predominantly due to the lack of randomized clinical trials (RCTs). Despite its rapidly increasing incidence, LM remains a rare complication of NSCLC. The very limited number of patients significantly restricts the implementation of RCTs.

Recently, it was noted that WBRT may have no contribution to the survival time of patients with LM from NSCLC ([@b3-ol-0-0-4783],[@b10-ol-0-0-4783]). It has been proposed that ITC may offer more benefits, according to the results of two retrospective studies analyzing the connection between treatment and clinical outcome in NSCLC patients with LM ([@b2-ol-0-0-4783]). Thus, in order to better evaluate ITC as a treatment for these particular patients, a pooled analysis of eligible clinical studies was conducted in the present study.

Patients and methods
====================

### Studies

A systematic search of the (<http://www.ncbi.nlm.nih.gov/pubmed>), OVID (<http://ovidsp.ovid.com/autologin.html>), EBSCO (<http://search.ebscohost.com>), and Cochrane Library databases (<http://www.thecochranelibrary.com>) was performed to identify all clinical studies that contained NSCLC patients with LM that were treated by ITC. The search strategy included articles indexed under the subject headings 'cancer', 'tumor', 'carcinoma', 'neoplasm', 'carcinomatosis', 'malignancy', 'meningitis', 'meningeal', 'leptomeningeal', 'metastasis' and 'metastases'. The latest search was conducted on July 31, 2014. The language was limited to English. Reviews and case reports were excluded. Different types of studies were included via different criteria.

Prospective studies were included according to the following criteria: i) diagnosis of LM complies with the National Comprehensive Cancer Network (NCCN) guidelines ([@b19-ol-0-0-4783]); ii) ITC was administered in prospective manner, even if few patients received concurrent systemic chemotherapy; and iii) contains individually assessable information regarding the therapeutic response or survival of NSCLC patients with LM. Finally, 4 prospective studies investigating ITC were included ([@b7-ol-0-0-4783],[@b20-ol-0-0-4783]--[@b22-ol-0-0-4783]). No control group was set in all 4 studies.

Retrospective studies were included according to the following criteria: i) Diagnosis of LM complies with the NCCN guidelines ([@b19-ol-0-0-4783]); ii) only analyzed NSCLC patients with LM; and iii) contains comparable information regarding response rate or survival related to ITC. There were 5 retrospective studies analyzing LM from NSCLC that were included ([@b1-ol-0-0-4783],[@b10-ol-0-0-4783],[@b12-ol-0-0-4783],[@b23-ol-0-0-4783],[@b24-ol-0-0-4783]).

### Patients

In each prospective study, only the patients diagnosed with LM from NSCLC were pooled for analysis. As the prospective studies did not mention which patients were treated by concurrent systemic chemotherapy, these patients could not be analyzed separately. All patients in the included retrospective studies were analyzed. However, all retrospective studies did not provide the individual information of each patient. Hence, the data of prospective and retrospective studies could not be reorganized.

### Reevaluation of therapeutic response

As no standardized criteria for the evaluation of therapeutic response had been defined or universally agreed at the time that the included prospective studies were conducted ([@b16-ol-0-0-4783]), there were some differences in criteria among these studies. For the feasibility of reevaluating data from different studies, therapeutic responses of each reevaluable patient were graded again via the unified criteria defined in the present study (as follows).

Clinical criteria were defined as follows: Complete response (CR), resolution of all neurological signs; partial response (PR), incomplete resolution of neurological signs; stable disease (SD), no change in clinical signs; progressive disease (PD), worsening of preexisting or new neurological signs. Neuroradiographic criteria were defined as follows: CR, resolution of all neuroradiographic signs; PR, incomplete resolution of neuroradiographic signs; SD, no change in neuroradiographic signs; PD, worsening of preexisting or new neuroradiographic signs. For cytological response, the definitions of CR, PR, SD and PD were difficult to determine because of the variety of original criteria in the included studies. Thus, cytological response was graded only into two levels: With response \[improved cerebrospinal fluid (CSF) cytology\]; and without response (worsening CSF cytology or no change). Although this grading is simple, it was the optimal option available for the present analysis.

The present clinical and neuroradiographic criteria are the same as the criteria defined by Chamberlain *et al* ([@b7-ol-0-0-4783]). As the retrospective studies did not provide individual information, the response rates of these reports were combined only when necessary.

### Reevaluation of survival

The time of survival of reevaluable patients was calculated on the basis of the records of each original study. The start point of survival was the onset of LM-directed therapy in prospective studies, and the diagnosis of LM in retrospective studies. The end point of survival was mortality of the patient. If the patient was alive at the end of study, the recorded time was considered to be their overall survival. Survival curves were constructed using the Kaplan-Meier method and SPSS 19.0 software (IBM, Armonk, NY, USA).

### Comparison among different studies (groups)

As the data of prospective and retrospective studies could not be reorganized, a simple comparison among the included studies was conducted. To do this, these studies were first renumbered via a suitable index: Response rate was used as the numbering index for the comparison of therapeutic response; and median survival was used as the numbering index for the comparison of survival. Then, studies were ranked by this number to compare relevant information.

Results
=======

### Studies

The basic information of the included studies is summarized in [Table I](#tI-ol-0-0-4783){ref-type="table"}. The original eligibility criteria of patients, criteria of diagnosis and evaluation of the included studies are summarized in [Tables II](#tII-ol-0-0-4783){ref-type="table"}, [III](#tIII-ol-0-0-4783){ref-type="table"} and [IV](#tIV-ol-0-0-4783){ref-type="table"}, respectively.

### Patients

According to the eligibility criteria defined in the present study, 69 patients in prospective studies and 520 patients in retrospective studies were pooled for analysis. In detail, 68 patients were reevaluable for analysis of response rate, 50 patients were reevaluable for analysis of survival and 589 patients were available for comparison ([Fig. 1](#f1-ol-0-0-4783){ref-type="fig"}). In total, 37 patients received ITC only, and 552 patients received multiple interventions (ITC, whole-brain radiotherapy, EGFR TKI, systemic chemotherapy, and/or support care). The basic information of pooled patients is summarized in [Table V](#tV-ol-0-0-4783){ref-type="table"}, and the individual information of reevaluable patients is listed in [Table VI](#tVI-ol-0-0-4783){ref-type="table"}.

### Results of reevaluating patients

The cytological, clinical and neuroradiographic response rates were 55% (53--60%; n=49), 64% (53--79%; n=58), and 53% (n=32), respectively (a response was defined as CR plus PR for clinical and neuroradiological responses). Taking SD into account, the clinical response rate was 100% when ITC was given by ventriculolumbar perfusion. The median survival time was 6.0 months (95% CI, 5.2--6.8; [Fig. 2A](#f2-ol-0-0-4783){ref-type="fig"}). The log-rank test calculated a P-value of 0.017 for the three comparable groups.

Results of comparing studies. For comparison of therapeutic response, the studies with available response rates were ranked according to ascending response rate, and then the detailed design of matched regimens was summarized ([Table VII](#tVII-ol-0-0-4783){ref-type="table"}). The percentage of symptomatic improvement was markedly higher in studies in which the patients received ITC only ([@b20-ol-0-0-4783],[@b22-ol-0-0-4783]). If SD is taken into account, the clinical response rate was 100% in these studies. Notably, the majority of the patients in these particular studies had a poor performance status (PS) ([Table V](#tV-ol-0-0-4783){ref-type="table"}). These results reveal that ITC with a suitable regimen may offer a promising response rate, particularly for the improvement of clinical symptoms.

All matched survival information of the analyzed patients in different studies is illustrated in [Fig. 2B](#f2-ol-0-0-4783){ref-type="fig"}. The total and ITC-related median survival times of pooled patients were all \>2 months (range, 3.0--18.0 months). Notably, all of the total median survival times of patients receiving multiple interventions (3.0--5.0 months) ([@b1-ol-0-0-4783],[@b7-ol-0-0-4783],[@b10-ol-0-0-4783],[@b12-ol-0-0-4783],[@b23-ol-0-0-4783],[@b24-ol-0-0-4783]) have a narrower range and are shorter than that of patients receiving ITC only (7.5 months) ([@b21-ol-0-0-4783],[@b22-ol-0-0-4783]). Furthermore, the start point of survival in patients receiving ITC only is later than that in patients receiving multiple interventions. Additionally, the percentages of each intervention among the different studies were evidently different.

LM patients with poor PS have a poor prognosis ([@b19-ol-0-0-4783]). However, in the study with the highest percentage of patients having poor PS ([Table II](#tII-ol-0-0-4783){ref-type="table"}), the median survival time was the longest (8.0 months) ([@b22-ol-0-0-4783]). These results indicate that ITC may offer survival benefits under a suitable regimen. However, the shorter median survival time and narrower range of patients receiving multiple interventions is not associated with poor prognosis, as these patients had better PS ([Table V](#tV-ol-0-0-4783){ref-type="table"}).

All of the retrospective studies included patients enrolled between 2000 and 2010 ([Table I](#tI-ol-0-0-4783){ref-type="table"}). Only two studies ([@b23-ol-0-0-4783],[@b24-ol-0-0-4783]) excluded some of the patients according to their eligibility criteria ([Table II](#tII-ol-0-0-4783){ref-type="table"}). Furthermore, the regimens of ITC among the retrospective studies were also similar ([Tables I](#tI-ol-0-0-4783){ref-type="table"} and [VII](#tVII-ol-0-0-4783){ref-type="table"}). However, the studies involving multiple interventions had significant heterogeneity with regard to numerous characteristics, such as race and the percentages of patients with poor PS and ITC ([Tables I](#tI-ol-0-0-4783){ref-type="table"} and [V](#tV-ol-0-0-4783){ref-type="table"}; [Fig. 3](#f3-ol-0-0-4783){ref-type="fig"}). Additionally, the differences in the percentages of patients with poor PS and receiving ITC cannot explain the differences in median survival time among the studies involving multiple interventions. Hence, there must be other important factors causing the shortening median survival time and narrowing of the range in patients receiving multiple interventions.

For better understanding, the studies with available survival information were ranked according to the ascending order of the median survival time values ([Table VIII](#tVIII-ol-0-0-4783){ref-type="table"}). The matched percentage of patients receiving each intervention was also calculated and listed in [Table VIII](#tVIII-ol-0-0-4783){ref-type="table"}. Notably, the significant shortening of median survival time was accompanied by a high percentage of patients receiving multiple interventions. The effect was enhanced when the interventions were given concurrently. These results suggest that the shortening of median survival time and narrowing of the range were caused by the reduction of body tolerance during repeated treatments, and also the aggravation of side effects during combination therapy.

### Bias

The current study is a pooled analysis. All the data of patients came from published studies. Selection and publication biases must be considered. Without any doubt, these biases would be overcome via an RCT. However, the extremely low incidence of LM makes the implementation of RCTs very challenge and time-consuming. Prior to the publication of any convincing RCTs, the current study indeed offers some suggestions for clinical practice.

Discussion
==========

The current study presented a pooled analysis including the largest number of NSCLC patients with LM. Although many prospective studies have been conducted to investigate drug therapy for LM from solid tumors (including NSCLC) ([@b6-ol-0-0-4783],[@b25-ol-0-0-4783]--[@b37-ol-0-0-4783]), they were not available according to the criteria defined in the current study. However, these studies still offer useful information for selecting suitable experimental drugs and regimens in clinical trials that are aiming to investigate ITC for the treatment of NSCLC patients with LM ([Table IX](#tIX-ol-0-0-4783){ref-type="table"}).

As there was no individually assessable information, it was not possible to reevaluate side effects that occurred in evaluable patients. According to the reporting of each study, the incidence of side effects was low, and the symptoms were mild, usually manifesting as slight headache, nausea and fever. There was an increasing trend in the incidence of side effects in patients receiving more treatments ([@b7-ol-0-0-4783]).

Compared with each study, higher response rates are achieved under suited regimen, particularly under relatively intensive regimens (e.g., more drug types, higher doses or longer administration time; [Table VII](#tVII-ol-0-0-4783){ref-type="table"}). Although the higher response rates were predominantly reported by studies with relative small sample sizes, the low rates reported in the two retrospective studies with a large sample number ([@b1-ol-0-0-4783],[@b23-ol-0-0-4783]) still support the need for relatively intensive regimens. Considering patients also received other kinds of interventions when necessary (prior to enrolling in the original clinical trial), we speculate that the need for relatively intensive regimen is determined by the biological features of NSCLC or the drug tolerance induced by repeated treatments. As the reported side effects are slight, and serious side effects are rare, it is worth trying relatively intensive regimens in patients who are able to tolerate it well. In fact, Nakagawa *et al* ([@b21-ol-0-0-4783]) attempted to determine patient tolerance by daily dose and weekly dosage schedule, in order to achieve better efficacy.

The median survival times of pooled patients were all \>2 months. Notably, in patients treated predominantly by ITC, the longest median survival time was observed (6.0 months). This may be explained by the type of patients pooled in the current analysis: Clinical trials reporting shorter median survival times usually enrolled patients with different types of tumor to expand the sample size ([Table IX](#tIX-ol-0-0-4783){ref-type="table"}) ([@b38-ol-0-0-4783]).

Tolerance is one of the important factors that requires consideration when multiple interventions are administered to a patient. LM from NSCLC indicates the end-stage of disease that is usually associated with poor PS and low body tolerance. Thus, suitable combination strategies of multidisciplinary therapy are extremely important for NSCLC patients with LM. Besides the studies included in the current analysis, other authors also retrospectively reported that the median survival time of 30 NSCLC patients with LM was 6.0 months, with 53% of patients receiving modern systemic therapy defined as a regimen containing pemetrexed, bevacizumab or a TKI ([@b39-ol-0-0-4783]). Another two Phase II clinical trials also reported that lung cancer patients receiving concurrent ITC and radiotherapy \[3 out of 5 patients ([@b36-ol-0-0-4783]) and 7 out of 8 patients ([@b37-ol-0-0-4783])\] exhibited short survival times without response ([@b36-ol-0-0-4783],[@b37-ol-0-0-4783]). The indication for radiotherapy in such patients must be better defined, considering that WBRT does not appear to contribute to survival ([@b3-ol-0-0-4783],[@b10-ol-0-0-4783]).

EGFR TKI treatment is also considered to be a significant intervention, particularly to patients with sensitive mutations ([@b1-ol-0-0-4783],[@b11-ol-0-0-4783]--[@b13-ol-0-0-4783],[@b23-ol-0-0-4783],[@b24-ol-0-0-4783]). Although it was reported that EGFR TKI offered higher response rate ([@b14-ol-0-0-4783]) and longer survival time ([@b12-ol-0-0-4783]) compared with other interventions, the studies ([@b12-ol-0-0-4783],[@b14-ol-0-0-4783]) are still retrospective and has a smaller patient number. Meanwhile, the selectivity of EGFR TKI treatment limits the scope of application, and patients are increasingly administered EGFR TKI treatment prior to the diagnosis of LM, which can lead to the development of drug tolerance. Incomplete penetration of the drug is considered to be one of the reasons for treatment failure ([@b40-ol-0-0-4783]--[@b42-ol-0-0-4783]). Although erlotinib exhibits improved capability of penetration ([@b43-ol-0-0-4783]) and disease control ([@b14-ol-0-0-4783]) compared with other EGFR TKIs, ITC remains a more direct, less selective and also well tolerated method of treatment. As the status of EGFR mutation is not clear for all of the pooled patients, it is not possible to compare the two interventions in the current study. Future clinical studies should perform a comparison between ITC and EGFR TKI treatment.

Recently, experts in LM developed a consensus proposal \[Response Assessment in Neuro-Oncology (RANO) criteria\] for evaluating the response to treatment of patients with LM ([@b44-ol-0-0-4783]), considering the lack of standardization and the importance of criteria for future clinical trials ([@b38-ol-0-0-4783]). Unfortunately, this new criteria was not practicable in the current study. If the new criteria are used, ITC may not offer such promising response rate, as the new criteria pay more attention to the cytological and radiographic responses. However, in NSCLC patients with LM, survival is the most important indicator of response evaluation, based on the analyzed results of median survival time. In other words, symptomatic improvement is the main target for the treatment of LM in patients with poor prognosis. This must be considered during the design of future clinical trials, and investigators must also consider the feasibility of the new RANO criteria in patients with varying prognoses.

In summary, for NSCLC patients with LM, ITC may offer promising response rates and survival benefits under suitable regimen. A suitable combination strategy of multidisciplinary therapy is important to NSCLC patients with LM.

The authors greatly appreciate the valuable comments and helpful assistance of Dr Kehong Zhang (The Ivy Editing, Shanghai, China) in preparing the manuscript.
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###### 

Design information of the included studies.

  Author, year                Type   Region   Time of enrolling   N      Objective                                                                                                                                                                      Regimen of ITC                                                 Ref.
  --------------------------- ------ -------- ------------------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------- ----------------------
  Chamberlain *et al*, 1998   P      USA      1986/07-1996/06       32   To evaluate survival, cause of mortality, and treatment-related toxic effects in patients undergoing combined modality therapy                                                 MTX, first-line; Ara-C, second-line; ThioTEPA, third-line      ([@b7-ol-0-0-4783])
  Gwak *et al*, 2013          P      Korea    2009/01-2010/04       22   To define the maximum tolerated dose, toxicities and pharmacokinetics of VLP chemotherapy, according to different modes of administration, perfusion rate and daily MTX dose   MTX, 24--60 mg daily, bolus or continuous injection, VLP       ([@b20-ol-0-0-4783])
  Nakagawa *et al*, 1999      P      Japan    1996/01-1998/09       23   To determine the suited dose of intrathecal 5-FdUrd                                                                                                                            5-FdUrd, dose and schedule are variable                        ([@b21-ol-0-0-4783])
  Nakagawa *et al*, 1996      P      Japan    N/A                   13   To evaluate the efficacy and side effects of VLP therapy with MTX and Ara-C                                                                                                    MTX, 10--30 mg/8--12 h; Ara-C, 40 mg/8--12 h, VLP              ([@b22-ol-0-0-4783])
  Lee *et al*, 2013           R      Korea    2001--2009          149    To identify the clinical features and prognostic factors of NSCLC patients with LM                                                                                             MTX                                                            ([@b1-ol-0-0-4783])
  Morris *et al*, 2012        R      USA      2002/01-2009/12     125    To assess the impact of WBRT, ITC and EGFR TKIs on outcomes                                                                                                                    MTX or liposomal Ara-C                                         ([@b10-ol-0-0-4783])
  Umemura *et al*, 2012       R      Japan    2001/07-2010/09       91   To examine the prognosis of patients with LM from NSCLC, and that stratified by EGFR mutation status in LM patients receiving EGFR TKIs                                        MTX or Ara-C or PSL or MTX/Ara-C or MTX/PSL or MTX/Ara-C/PSL   ([@b12-ol-0-0-4783])
  Gwak *et al*, 2013          R      Korea    2002/09-2010/12     105    To report clinical outcomes of ITC for LM from NSCLC                                                                                                                           MTX or MTX/Ara-C/hydrocortisone                                ([@b23-ol-0-0-4783])
  Park *et al*, 2012          R      Korea    2003--2009            50   To analyze the patterns of treatment and clinical outcomes of LM in patients with NSCLC in the modern chemotherapy era                                                         MTX or ThioTEPA or MTX/Ara-C/hydrocortisone                    ([@b24-ol-0-0-4783])

N, number; Ref., reference; R, retrospective; P, prospective; NSCLC, non-small cell lung cancer; VLP, ventriculolumbar perfusion; MTX, methotrexate; Ara-C, cytarabine; 5-FdUrd, 5-fluoro-2′-deoxyuridine; PSL, prednisolone; LM, leptomeningeal metastasis; WBRT, whole-brain radiotherapy; ITC, intrathecal chemotherapy; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors.

###### 

Original eligibility criteria of patients in the included studies.

                              Inclusion criteria                                                                                                                                                                                                                                                                                    
  --------------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ----------------------
  Chamberlain *et al*, 1998   LM                   Karnofsky performance status ≥70; expected survival ≥3 months; no prior ITC patients; desire for further therapy                                                              Patients not matching the inclusion criteria                                                       ([@b7-ol-0-0-4783])
  Gwak *et al*, 2013          LM                   Symptoms of hydrocephalus; increased intracranial pressure (\>15 cm H~2~O) measured at the subgaleal reservoir; either cauda equina symptoms or signs of cranial neuropathy   Mass effects                                                                                       ([@b20-ol-0-0-4783])
  Nakagawa *et al*, 1999      LM                   --                                                                                                                                                                            --                                                                                                 ([@b21-ol-0-0-4783])
  Nakagawa *et al*, 1996      LM                   --                                                                                                                                                                            An apparent spinal mass and spinal block on magnetic resonance imaging                             ([@b22-ol-0-0-4783])
  Lee *et al*, 2013           LM from NSCLC        --                                                                                                                                                                            --                                                                                                 ([@b1-ol-0-0-4783])
  Morris *et al*, 2012        LM from NSCLC        --                                                                                                                                                                            --                                                                                                 ([@b10-ol-0-0-4783])
  Umemura *et al*, 2012       LM from NSCLC        --                                                                                                                                                                            --                                                                                                 ([@b12-ol-0-0-4783])
  Gwak *et al*, 2013          LM from NSCLC        Patients who had undergone installation of a subgaleal intraventricular reservoir after informed consent, and received intraventricular chemotherapy for LM                   Patients refused ITC, or received ITC through lumbar puncture                                      ([@b23-ol-0-0-4783])
  Park *et al*, 2012          LM from NSCLC        --                                                                                                                                                                            Patients with radiological evidence of LM not confirmed by positive cerebrospinal fluid cytology   ([@b24-ol-0-0-4783])

Ref., reference; LM, leptomeningeal metastasis; NSCLC, non-small cell lung cancer; ITC, intrathecal chemotherapy; -, no other requirement.

###### 

Original diagnosis criteria of LM in included studies.

  Author, year                Original diagnostic criteria                                                                                                                                                                                                                                                                                                Ref.
  --------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  Chamberlain *et al*, 1998   Positive CSF cytological finding, or CSF abnormalities and clinical syndrome or neuroradiographic findings consistent with LM                                                                                                                                                                                               ([@b7-ol-0-0-4783])
  Gwak *et al*, 2013          Positive CSF cytology result                                                                                                                                                                                                                                                                                                ([@b20-ol-0-0-4783])
  Nakagawa *et al*, 1999      Positive CSF cytology result                                                                                                                                                                                                                                                                                                ([@b21-ol-0-0-4783])
  Nakagawa *et al*, 1996      Positive CSF cytology result                                                                                                                                                                                                                                                                                                ([@b22-ol-0-0-4783])
  Lee *et al*, 2013           Positive CSF cytology result; CSF exploration was only performed in patients who developed neurological problems or had abnormal brain imaging                                                                                                                                                                              ([@b1-ol-0-0-4783])
  Morris *et al*, 2012        Cytological evidence of malignant cells on CSF; or neuroimaging (gadolinium enhanced T1-weighted MRI) consistent with LM, as defined by the presence of multifocal enhancing subarachnoid nodules                                                                                                                           ([@b10-ol-0-0-4783])
  Umemura *et al*, 2012       Diagnosis of LM was based on the detection of malignant cells in CSF, the typical findings of subarachnoid tumor cell deposits on MRI, or both                                                                                                                                                                              ([@b12-ol-0-0-4783])
  Gwak *et al*, 2013          Diagnosis of LM was based on either the presence of malignant cells in the CSF or on typical neuroimaging findings (clear leptomeningeal enhancement in cerebral sulci, cerebellar foliae, spinal cord, cauda equina, or subependymal lining on the MRI) in patients with an established diagnosis of systemic malignancy   ([@b23-ol-0-0-4783])
  Park *et al*, 2012          Cytological identification of malignant cells within CSF                                                                                                                                                                                                                                                                    ([@b24-ol-0-0-4783])

Ref., reference; LM, leptomeningeal metastasis; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging.

###### 

Original criteria of response evaluation in studies available for comparison of therapeutic response.

  Author, year                Original criteria of response evaluation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             Ref.
  --------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------
  Chamberlain *et al*, 1998   Cytological criteria: CR, 2 consecutive negative CSF (ventricular and lumbar sampling) cytological examinations at least 1 week apart and sustained for at least 1 month on a regimen of stable or decreasing steroid dosage; PR, conversion from positive to suspicious on 2 consecutive CSF (ventricular and lumbar sampling) cytological examinations at least 1 week apart and sustained for at least 1 month on a regimen of stable or decreasing steroid dosage; PD, conversion from negative 2 consecutive examinations to positive, or 2 consecutive positive or suspicious cytological findings. Clinical criteria: CR, resolution of all neurologic signs; PR, incomplete resolution of neurologic signs; SD, no change in clinical signs; PD, worsening of preexisting or new neurologic signs. Neuroradiographic criteria: CR, resolution of all neuroradiographic signs; PR, incomplete resolution of neuroradiographic signs; SD, no change in neuroradiographic signs; PD, worsening of preexisting or new neuroradiographic signs.   ([@b7-ol-0-0-4783])
  Gwak *et al*, 2013          Post-treatment ICPs were measured 3 days after cessation of the VLP (i.e. day 7), to avoid the immediate effect of VLP (drainage) on the CSF flow. The other pretreatment symptoms and signs were checked 10 days after completion of the therapy (day 14).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          ([@b20-ol-0-0-4783])
  Nakagawa *et al*, 1999      Cytological criteria: CR, negative cytology and normal cell counts and tumor marker levels (cell count ≤10/mm^3^ and 50 mg/dl protein) in both ventricular and spinal CSF; PR, ≥50% reduction in either ventricular or spinal CSF malignant cell count; SD, failure to fulfill criteria for either a response or progressive disease; PD, positive cytology in either ventricular or spinal CSF.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     ([@b21-ol-0-0-4783])
  Nakagawa *et al*, 1996      Once a week, before and after perfusion therapy, routine and cytological examination of the CSF was performed. Clinical criteria: Good, CSF findings were negative, in association with a moderate to marked improvement of neurological deficits and the ability to walk unassisted; moderate, improvement of both CSF parameters and neurological deficits, regardless of the degree of change; minor, improvement of either the CSF parameters or the neurological deficits; none, no improvement of either their neurological deficits or CSF parameters.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        ([@b22-ol-0-0-4783])
  Lee *et al*, 2013           No specific evaluation, just mentioned 'ITC was administered to 109 patients (73.2%), and the median number of ITC administrations was 9 (range, 1--27); only 15 patients achieved cytologically negative conversion' in the text.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   ([@b1-ol-0-0-4783])
  Gwak *et al*, 2013          Changes of ICP; other LM-related symptoms were evaluated tentatively as normalized, improved, stationary, and worsen based on patients\' subjective statements and a physician\'s description retrieved from the medical records; cytological criteria are the same as Chamberlain *et al* in Ref. [@b6-ol-0-0-4783].                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ([@b23-ol-0-0-4783])
  Park *et al*, 2012          The response of LM to ITC was evaluated by cytological findings of the CSF. An objective systemic response to systemic chemotherapy was assessed by the Response Evaluation Criteria In Solid Tumors.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                ([@b24-ol-0-0-4783])

Ref., reference; CR, complete response; CSF, cerebrospinal fluid; PR, partial response; PD, progressive disease; SD, stable disease; ICP, intracranial pressure; VLP, ventriculolumbar perfusion; ITC, intrathecal chemotherapy; LM, leptomeningeal metastasis.

###### 

Patient characteristics (only patients enrolled in the current study) of included studies.

                                      Histology (NSCLC)                                                                                                                                               
  --------------------------- ------- ------------------- ---- ---- ----- ------- --------------- ------------------------------------------------- ------------------------------------------------- ----------------------
  Chamberlain *et al*, 1998     32      24                6    2      0   22/10   57 (48--73)     90 (70--100)                                      0                                                 ([@b7-ol-0-0-4783])
  Gwak *et al*, 2013            19      18                1    0      0   7/12    52 (37--67)     60 (40--90)                                       47.4                                              ([@b20-ol-0-0-4783])
  Nakagawa *et al*, 1999        11      11                0    0      0   3/8     59 (48--73)     --^[b](#tfn6-ol-0-0-4783){ref-type="table-fn"}^   --^[b](#tfn6-ol-0-0-4783){ref-type="table-fn"}^   ([@b21-ol-0-0-4783])
  Nakagawa *et al*, 1996          7       5               1    1      0   2/5     52 (44--57)     --                                                71.4                                              ([@b22-ol-0-0-4783])
  Lee *et al*, 2013           149     135                 --   --   14    76/73   58 (34--80)     --                                                13.4                                              ([@b1-ol-0-0-4783])
  Morris *et al*, 2012        125       97                2    4    22    45/80   59 (28--87)     70 (30--100)                                      --                                                ([@b10-ol-0-0-4783])
  Umemura *et al*, 2012         91      83                2    2      4   47/44   62 (35--79)     --                                                42.9                                              ([@b12-ol-0-0-4783])
  Gwak *et al*, 2013          105     101                 2    2      0   44/61   56 (31--75)     70 (40--90)                                       47.6                                              ([@b23-ol-0-0-4783])
  Park *et al*, 2012            50      42                --   3      5   25/25   62.5 (34--81)   --                                                30.0                                              ([@b24-ol-0-0-4783])

Poor PS indicates KPS \<70 or ECOG PS \>2

although there is no individual information about PS of NSCLC patients, \>57% of total patients had a poor PS (KPS \<70 or ECOG PS \>2) in Ref. [@b21-ol-0-0-4783]. N, number; NSCLC, non-small cell lung cancer; AD, adenocarcinoma; LCC, large cell carcinoma; SQ, squamous cell carcinoma; KPS, Karnofsky performance status; PS, performance status; Ref., reference; -, unavailable; ECOG, Eastern Cooperative Oncology Group.

###### 

The individual information of enrolled prospective patients.

                              Patient no.                           Data available for                         
  --------------------------- ------------- ---------- ------------ -------------------- ---------- ---------- ----------------------
  Chamberlain *et al*, 1998     1             1        49           22 M/10 F            Y          Y          ([@b7-ol-0-0-4783])
                                2             2        63                                Y          Y          
                                3             3        61                                Y          Y          
                                4             4        58                                Y          Y          
                                5             5        60                                Y          Y          
                                6             6        73                                Y          Y          
                                7             7        59                                Y          Y          
                                8             8        62                                Y          Y          
                                9             9        56                                Y          Y          
                              10            10         58                                Y          Y          
                              11            11         60                                Y          Y          
                              12            12         62                                Y          Y          
                              13            13         61                                Y          Y          
                              14            14         58                                Y          Y          
                              15            15         54                                Y          Y          
                              16            16         56                                Y          Y          
                              17            17         62                                Y          Y          
                              18            18         65                                Y          Y          
                              19            19         52                                Y          Y          
                              20            20         49                                Y          Y          
                              21            21         61                                Y          Y          
                              22            22         60                                Y          Y          
                              23            23         58                                Y          Y          
                              24            24         56                                Y          Y          
                              25            25         54                                Y          Y          
                              26            26         62                                Y          Y          
                              27            27         48                                Y          Y          
                              28            28         51                                Y          Y          
                              29            29         62                                Y          Y          
                              30            30         49                                Y          Y          
                              31            31         51                                Y          Y          
                              32            32         56                                Y          Y          
  Gwak *et al*, 2013          33              1        53           M                    Y          N          ([@b20-ol-0-0-4783])
                              34              2        63           M                    Y          N          
                              35              3        45           M                    Y          N          
                              36              4        45           M                    Y          N          
                              37              5        45           M                    Y          N          
                              38              7        52           M                    Y          N          
                              39              8        49           F                    Y          N          
                              40              9        50           F                    Y          N          
                              41            11         37           F                    Y          N          
                              42            12         62           F                    Y          N          
                              43            13         49           F                    Y          N          
                              44            14         49           F                    Y          N          
                              45            16         67           F                    Y          N          
                              46            17         67           F                    Y          N          
                              47            18         62           M                    Y          N          
                              48            19         52           F                    Y          N          
                              49            20         56           F                    Y          N          
                              50            21         51           F                    Y          N          
                              51            22         42           F                    Y          N          
  Nakagawa *et al*, 1999      52              1        63           F                    Y          Y          ([@b21-ol-0-0-4783])
                              53              2        65           F                    N          Y          
                              54              3        49           F                    Y          Y          
                                                                                                               
                              Patient no.                           Available for                              
                                                                                                               
  Author, year                New           Original   Age, years   Gender               Response   Survival   Ref.
                                                                                                               
  Nakagawa *et al*, 1999      55              4        56           F                    Y          Y          ([@b21-ol-0-0-4783])
                              56              7        48           F                    Y          Y          
                              57              8        70           M                    Y          Y          
                              58            18         53           F                    Y          Y          
                              59            19         57           F                    Y          Y          
                              60            20         58           F                    Y          Y          
                              61            21         73           M                    Y          Y          
                              62            22         63           M                    Y          Y          
  Nakagawa *et al*, 1996      63              1        54           F                    Y          Y          ([@b22-ol-0-0-4783])
                              64              2        57           M                    Y          Y          
                              65              3        49           F                    Y          Y          
                              66              8        54           F                    Y          Y          
                              67            10         51           F                    Y          Y          
                              68            11         56           F                    Y          Y          
                              69            12         44           M                    Y          Y          
  Total                       69                                                         68         50         

Ref., reference; M, male; F, female; Y, yes; N, no.

###### 

Detailed ITC regimen designs of comparable retrospective and prospective studies.

      Response rate (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  --- -------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------- ------------------ ----------- ---------------------------------------------------------------------- ---- ---- ---------- ----------------------
  1   14^[b](#tfn9-ol-0-0-4783){ref-type="table-fn"}^    --                                                     Lee *et al*, 2013                                                         MTX                                                                                                                                                                            15 mg                x2/w               Injection   1/w × 4 w, 1/2 w × 3 m^[g](#tfn14-ol-0-0-4783){ref-type="table-fn"}^   9    CC   MT         ([@b1-ol-0-0-4783])
  2   25^[c](#tfn10-ol-0-0-4783){ref-type="table-fn"}^   13--42^[c](#tfn10-ol-0-0-4783){ref-type="table-fn"}^   Gwak *et al*, 2013                                                        MTX (38^[f](#tfn13-ol-0-0-4783){ref-type="table-fn"}^) Triple (62^[f](#tfn13-ol-0-0-4783){ref-type="table-fn"}^)                                                               15 mg Triple         x2/w ×2/w          Injection   --                                                                     5         Progress   ([@b23-ol-0-0-4783])
  3   52^[b](#tfn9-ol-0-0-4783){ref-type="table-fn"}^    50^[c](#tfn10-ol-0-0-4783){ref-type="table-fn"}^       Park *et al*, 2012                                                        MTX (48^[f](#tfn13-ol-0-0-4783){ref-type="table-fn"}^) Triple (69^[f](#tfn13-ol-0-0-4783){ref-type="table-fn"}^) ThioTEPA (31^[f](#tfn13-ol-0-0-4783){ref-type="table-fn"}^)   15 mg Triple 10 mg   x2/w ×2/w ×2/w     Injection   2/w                                                                    1    CC   Progress   ([@b24-ol-0-0-4783])
  4   53^[d](#tfn11-ol-0-0-4783){ref-type="table-fn"}^   53^[d](#tfn11-ol-0-0-4783){ref-type="table-fn"}^       Chamberlain *et al*, 1998^[e](#tfn12-ol-0-0-4783){ref-type="table-fn"}^   MTX                                                                                                                                                                            2 mg                 x5 cds/2 w, ×8 w   Injection   5 cds/4 w                                                              --   SI   Progress   ([@b7-ol-0-0-4783])
  5   57^[d](#tfn11-ol-0-0-4783){ref-type="table-fn"}^   71^[d](#tfn11-ol-0-0-4783){ref-type="table-fn"}^       Nakagawa *et al*, 1996                                                    MTX/Ara-C                                                                                                                                                                      10--30/40 mg         x6 or 9/3 d        Perfusion   1/w^[h](#tfn15-ol-0-0-4783){ref-type="table-fn"}^                      --   CC   Progress   ([@b22-ol-0-0-4783])
  6   60^[d](#tfn11-ol-0-0-4783){ref-type="table-fn"}^   --                                                     Nakagawa *et al*, 1999                                                    5-FdUrd                                                                                                                                                                        1--10 mg             2--7/w             Injection   --                                                                     --   --   Progress   ([@b21-ol-0-0-4783])
  7   --                                                 79^[d](#tfn11-ol-0-0-4783){ref-type="table-fn"}^       Gwak *et al*, 2013                                                        MTX                                                                                                                                                                            24--60 mg            3 cds              Perfusion   1/w                                                                    --   SI   Progress   ([@b20-ol-0-0-4783])

Check for the beginning of MT

percentage of cytological negative conversion in patients receiving intrathecal chemotherapy

percentage of symptom improvement in patients receiving intrathecal chemotherapy

percentage of patients with response (complete response plus partial response for clinical and neuroradiological response)

only re-evaluated the response rates of first-line regimen

percentage of patients receiving different regimen

MT for 4 months

low-dose MT for 2 months. ITC, intrathecal chemotherapy; R, retrospective; P, prospective; CC, cytology cleared; SI, symptom improvement; MT, maintenance therapy; cds, consecutive days; w, week; m, month; d, day; ×2/w, twice per week; ×5 cds/2 w, ×8 w, 5 consecutive days per 2 weeks over 8 weeks; ×6 or 9/3d, 6--9 times over 3 days; Triple, 15 mg MTX, 30 mg/m^2^ cytarabine and 15 mg/m^2^ hydrocortisone; -, unavailable; Y, yes; MTX, methotrexate; Ara-C, cytarabine; 5-FdUrd, 5-fluoro-2′-deoxyuridine.

###### 

Percentages of intervention in included studies.

  MS rank   MS mOS   mOS-ITC                                                 Author, year                                                           ITC (%)   TKI (%)                                              SCT (%)                                               WBRT (%)                                              SC (%)   Ref.
  --------- -------- ------------------------------------------------------- ---------------------------------------------------------------------- --------- ---------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- -------- ----------------------
    1       3.0 mo   3.0 mo                                                  Gwak *et al*, 2013                                                     100.0     27.6^[c](#tfn18-ol-0-0-4783){ref-type="table-fn"}^   22.9^[c](#tfn18-ol-0-0-4783){ref-type="table-fn"}^    28.6^[c](#tfn18-ol-0-0-4783){ref-type="table-fn"}^    --       ([@b23-ol-0-0-4783])
    2       3.0 mo   18.0 mo^[a](#tfn16-ol-0-0-4783){ref-type="table-fn"}^   Morris *et al*, 2012                                                       6.0   14.0                                                 16.0                                                  45.0                                                  30.0     ([@b10-ol-0-0-4783])
    3       14 wks   17 wks                                                  Lee *et al*, 2013                                                        73.2    16.1                                                 16.8                                                  43.7                                                  13.4     ([@b1-ol-0-0-4783])
    4       3.6 mo   --                                                      Umemura *et al*, 2012                                                    29.7    56.0                                                 29.9                                                  23.1                                                  25.3     ([@b12-ol-0-0-4783])
    5       4.3 mo   --                                                      Park *et al*, 2012                                                       96.0    28.0                                                 24.0                                                  42.2^[c](#tfn18-ol-0-0-4783){ref-type="table-fn"}^    --       ([@b24-ol-0-0-4783])
    6       5.0 mo   5.0 mo                                                  Chamberlain *et al*, 1998                                              100.0       0.0                                                37.5^[c](#tfn18-ol-0-0-4783){ref-type="table-fn"}^    28.1^[d](#tfn19-ol-0-0-4783){ref-type="table-fn"}^      0.0    ([@b7-ol-0-0-4783])
    7       6.0 mo   6.0 mo                                                  Present study                                                          100.0       0.0                                                24.0^[c](#tfn18-ol-0-0-4783){ref-type="table-fn"}^    18.0^[d](#tfn19-ol-0-0-4783){ref-type="table-fn"}^      0.0    
    8       7.0 mo   7.0 mo                                                  Nakagawa *et al*, 1999^[b](#tfn17-ol-0-0-4783){ref-type="table-fn"}^   100.0       0.0                                                  0.0^[e](#tfn20-ol-0-0-4783){ref-type="table-fn"}^     0.0^[e](#tfn20-ol-0-0-4783){ref-type="table-fn"}^     0.0    ([@b21-ol-0-0-4783])
    9       7.5 mo   7.5 mo                                                  Present study^[c](#tfn18-ol-0-0-4783){ref-type="table-fn"}^            100.0       0.0                                                  0.0^[e](#tfn20-ol-0-0-4783){ref-type="table-fn"}^     0.0^[e](#tfn20-ol-0-0-4783){ref-type="table-fn"}^     0.0    
  10        8.0 mo   8.0 mo                                                  Nakagawa *et al*, 1996^[b](#tfn17-ol-0-0-4783){ref-type="table-fn"}^   100.0       0.0                                                  0.0                                                   0.0                                                   0.0    ([@b22-ol-0-0-4783])

Only 6 patients received ITC

Also calculated in the present study

concurrent with ITC

prior to ITC

Some patients in this study received WBRT or SCT prior to ITC, but the start point for calculating survival is the onset of ITC. MS, median survival; mOS, MS of all the patients; mOS-ITC, MS related to ITC; ITC, intrathecal chemotherapy; SCT, systemic chemotherapy; WBRT, whole-brain radiotherapy; SC, support care; Ref., reference; mo, months; wks, weeks; -, unavailable.

###### 

Relevant information in prospective studies investigating ITC.

                                                                        Number of patients                             Response, %                                                                                                       Median survival time (range)                                                                                                                               
  --------------------------------------------------------------------- -------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------------ --------------- ------------------------------------------------------ ---------------------------------------------------- ----------------------
  Wasserstrom *et al*, 1982                                               90                 23 ([@b17-ol-0-0-4783])   RT followed by ITC \[MTX (7 mg/m^2^) or ara-C (30 mg/m^2^)\]                                                      51.2                           17.4 (−)        5.8 mo ([@b1-ol-0-0-4783]--[@b29-ol-0-0-4783])         4.0 mo ([@b1-ol-0-0-4783]--[@b10-ol-0-0-4783]) / −   ([@b6-ol-0-0-4783])
  Hitchins *et al*, 1987                                                  42                 16 ([@b3-ol-0-0-4783])    MTX (15 mg), or MTX plus ara-C (50 mg/m^2^); concurrent RT when needed                                            55.0                           − (−)           8 wks (1--152)                                         − / −                                                ([@b25-ol-0-0-4783])
  Grossman *et al*, 1993                                                  52                 12 (−)                    MTX (10 mg) or thioTEPA (10 mg); concurrent RT when needed                                                        23.0                           33.3 (−)        15.86 wks (MTX) 14.14 wks (thioTEPA)                   − / −                                                ([@b26-ol-0-0-4783])
  Kim *et al*, 2003^[a](#tfn21-ol-0-0-4783){ref-type="table-fn"}^         55                 33 (−)                    MTX (15 mg), or MTX (15 mg) plus hydrocortisone (15 mg/m^2^) plus ara-C (30 mg/m^2^); concurrent RT when needed   25.5/65.5                      26.7 (16.0)     11.9 wks (2.7--28.7)                                   − / 10.4 vs. 23.9 wks                                ([@b27-ol-0-0-4783])
  Yoshida *et al*, 2005^[b](#tfn22-ol-0-0-4783){ref-type="table-fn"}^     58                 12 ([@b9-ol-0-0-4783])    MTX, ara-C and prednisolone                                                                                       62.1/53.4                      33.3/33.3 (−)   32.8 mo (lymphoma) 18.4 mo (breast) 15.4 mo (others)   13.0 mo / −                                          ([@b29-ol-0-0-4783])
  Glantz *et al*, 1999                                                    61                 10 ([@b6-ol-0-0-4783])    Sustained-release ara-C (DepoCyt) or MTX; concurrent RT when needed                                               23.0                           30.0 (16.7)     105 days (DepoCyt) 78 days (MTX)                       − / −                                                ([@b32-ol-0-0-4783])
  Groves *et al*, 2008                                                    62                 13 ([@b12-ol-0-0-4783])   Topotecan; concurrent RT when needed                                                                              21.0                           − (−)           15 wks ([@b13-ol-0-0-4783]--[@b24-ol-0-0-4783])        − / −                                                ([@b33-ol-0-0-4783])
  Jaeckle *et al*, 2002                                                 110                  28 ([@b14-ol-0-0-4783])   Sustained-release ara-C (DepoCyt); concurrent RT when needed                                                      40.0                           − (−)           95 days (7--791)                                       − / −                                                ([@b34-ol-0-0-4783])
  Chamberlain *et al*, 2002                                               22                   5 ([@b4-ol-0-0-4783])   α-interferon; concurrent RT when needed                                                                           45.0                           0.0 (0.0)       18 wks (5--69)                                         − / −                                                ([@b36-ol-0-0-4783])
  Chamberlain *et al*, 2006                                               27                   9 ([@b8-ol-0-0-4783])   Etoposide; concurrent RT when needed                                                                              26.0                           0.0 (0.0)       10 wks (4--52)                                         9 wks (5--11) / 9 wks (5--11)                        ([@b37-ol-0-0-4783])

Authors reported the cytological and neurological response rates.

Authors reported the cytological and clinical response rates. ITC, intrathecal chemotherapy; NSCLC, non-small cell lung cancer; Ref, reference; -, unavailable; RT, radiotherapy; ara-C, cytosine arabinoside (cytarabine); MTX, methotrexate; mo, months; wks, weeks. According to Ref. [@b8-ol-0-0-4783], [@b20-ol-0-0-4783], [@b25-ol-0-0-4783], and [@b37-ol-0-0-4783], pemetrexed, interleukin 2, and gemcitabine also might be considered as experiment drug.
